Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Lluch

Showing results (141-150 of 186) with videos related to

Pageof 19
Sort By:
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 4, 2009
Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patientsAlfredo Carrato, Luis Paz-Ares Rodríguez, Alvaro Rodríguez Lescure, et al.
Frontiers in Oncology|May 21, 2019
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast CancerTomás Pascual, Miguel Martin, Aranzazu Fernández-Martínez, et al.
The Oncologist|January 21, 2016
High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast CancerEmilio Alba, Ana Lluch, Nuria Ribelles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2022
Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant CapecitabineKarama Asleh, Ana Lluch, Angela Goytain, et al.
Journal of Drug Assessment|May 10, 2019
Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologistsPedro Sánchez-Rovira, Pilar Zamora, Javier Salvador-Bofill, et al.
Journal of the Academy of Nutrition and Dietetics|July 5, 2016
Evaluating the Applicability of Data-Driven Dietary Patterns to Independent Samples with a Focus on Measurement Tools for Pattern SimilarityAdela Castelló, Brian Buijsse, Miguel Martín, et al.
The Oncologist|June 19, 2016
High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast CancerEmilio Alba, Ana Lluch, Nuria Ribelles, et al.
Cell Metabolism|October 6, 2017
MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative PhosphorylationKyung-Min Lee, Jennifer M Giltnane, Justin M Balko, et al.
Clinical Proteomics|September 13, 2011
Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancerAna M Gonzalez-Angulo, Bryan T Hennessy, Funda Meric-Bernstam, et al.
Cancer Immunology Research|June 14, 2019
High Numbers of Circulating CD57<sup>+</sup> NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2<sup>+</sup> Primary Breast CancerAura Muntasell, Sònia Servitja, Mariona Cabo, et al.
Pageof 19

Showing results (141-150 of 186) with videos related to

Sort By:
Pageof 19
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|July 4, 2009
Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patientsAlfredo Carrato, Luis Paz-Ares Rodríguez, Alvaro Rodríguez Lescure, et al.
Frontiers in Oncology|May 21, 2019
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast CancerTomás Pascual, Miguel Martin, Aranzazu Fernández-Martínez, et al.
The Oncologist|January 21, 2016
High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast CancerEmilio Alba, Ana Lluch, Nuria Ribelles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 8, 2022
Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant CapecitabineKarama Asleh, Ana Lluch, Angela Goytain, et al.
Journal of Drug Assessment|May 10, 2019
Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of Spanish medical oncologistsPedro Sánchez-Rovira, Pilar Zamora, Javier Salvador-Bofill, et al.
Journal of the Academy of Nutrition and Dietetics|July 5, 2016
Evaluating the Applicability of Data-Driven Dietary Patterns to Independent Samples with a Focus on Measurement Tools for Pattern SimilarityAdela Castelló, Brian Buijsse, Miguel Martín, et al.
The Oncologist|June 19, 2016
High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast CancerEmilio Alba, Ana Lluch, Nuria Ribelles, et al.
Cell Metabolism|October 6, 2017
MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative PhosphorylationKyung-Min Lee, Jennifer M Giltnane, Justin M Balko, et al.
Clinical Proteomics|September 13, 2011
Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancerAna M Gonzalez-Angulo, Bryan T Hennessy, Funda Meric-Bernstam, et al.
Cancer Immunology Research|June 14, 2019
High Numbers of Circulating CD57<sup>+</sup> NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2<sup>+</sup> Primary Breast CancerAura Muntasell, Sònia Servitja, Mariona Cabo, et al.
Pageof 19